Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Juno Stresses Differences Between Its CAR-Ts As JCAR015 Trial Put On Hold Again

Executive Summary

Juno stressed structural differences, safety record and potential of its JCAR017 CAR-T therapy during a Nov. 23 call about the disappointing hold on its ROCKET ALL study for JCAR015 – the second clinical hold for the company’s most advanced development program.

You may also be interested in...



A Cellectis Trial Death Points To Challenges Ahead For CAR-T

Excitement over the emerging cancer immunotherapy approach has been super-charged in recent weeks, but Cellectis said it will put two trials on hold after a patient death, a problem seen with similar products.

Too Sick For CAR-T? Kite Reports Cerebral Edema Death

Kite Pharma investors were spooked on May 8 when the company revealed that an extremely ill patient died from cerebral edema related to its lead CAR-T candidate – the same severe side effect that derailed Juno's competing cell therapy.

Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position

Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097731

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel